Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

被引:27
|
作者
Kuwata, Hitoshi [1 ,2 ]
Yabe, Daisuke [1 ,3 ,4 ]
Murotani, Kenta [5 ]
Fujiwara, Yuuka [1 ]
Haraguchi, Takuya [1 ,2 ,3 ]
Kubota, Sodai [1 ,3 ]
Kubota-Okamoto, Saki [1 ,3 ]
Usui, Ryota [1 ,2 ]
Ishitobi, Minori [2 ]
Yamazaki, Yuji [1 ,2 ]
Hamamoto, Yoshiyuki [1 ,2 ]
Kurose, Takeshi [1 ,6 ]
Seino, Yusuke [7 ]
Yamada, Yuichiro [1 ,2 ]
Seino, Yutaka [1 ,2 ]
机构
[1] Kansai Elect Power Med Res Inst, Yutaka Seino Distinguished Ctr Diabet Res, Kobe, Hyogo, Japan
[2] Kansai Elect Power Hosp, Ctr Diabet Endocrinol & Metab, Osaka, Japan
[3] Gifu Univ, Grad Sch Med, Dept Diabet Endocrinol & Metab, Gifu, Japan
[4] Kobe Univ, Grad Sch Med, Div Mol & Metab Med, Kobe, Hyogo, Japan
[5] Kurume Univ, Grad Sch Med, Biostat Ctr, Kurume, Fukuoka, Japan
[6] Nakanoshima Clin, Osaka, Japan
[7] Fujita Hlth Univ, Dept Endocrinol & Metab, Toyoake, Aichi, Japan
关键词
Gastric emptying; GLP-1 receptor agonist; islet hormones; OPEN-LABEL; INCRETIN SECRETION; LIRAGLUTIDE; LIXISENATIDE; GLP-1; STIMULATION; GLUCOSE; SAFETY; GIP;
D O I
10.1111/jdi.13598
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Introduction Differences in the glucose-lowering mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. Materials and Methods A single-arm, prospective, observational study was conducted to evaluate the effects of various GLP-1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP-1RA initiation. Effects on postprandial secretions of glucose-dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. Results Eighteen subjects with type 2 diabetes received one of three GLP-1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12-week administration of all of the GLP-1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP-1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP-1RAs. Conclusions All of the GLP-1RAs were found to improve HbA1c in a 12-week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose-lowering effects and body weight reduction were observed.
引用
收藏
页码:2162 / 2171
页数:10
相关论文
共 50 条
  • [1] Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying
    Horowitz, Michael
    Rayner, Christopher K.
    Marathe, Chinmay S.
    Wu, Tongzhi
    Jones, Karen L.
    DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2504 - 2506
  • [2] Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
    Watchorn, David
    O'Shea, Donal
    Butler, Marcus W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (07) : 923 - 924
  • [3] Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Hansen, K. B.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1154 - 1160
  • [4] Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists
    Raven, Lisa M.
    Stoita, Alina
    Feller, Robert B.
    Brown, Campbell
    Greenfield, Jerry R.
    AMERICAN JOURNAL OF MEDICINE, 2023, 136 (12): : E233 - E234
  • [5] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [6] The effect of glucagon-like peptide-1 receptor agonists on postprandial glucagon secretion independent of the gastric emptying rate
    Frandsen, C. S.
    Ostergaard, L.
    Dejgaard, T. F.
    Sondergaard, B.
    Albrechtsen, N. J. Wewer
    Holst, J. J.
    Madsbad, S.
    DIABETOLOGIA, 2016, 59 : S381 - S381
  • [7] Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism
    Hansen, Morten S. S.
    Tencerova, Michaela
    Frolich, Jacob
    Kassem, Moustapha
    Frost, Morten
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 25 - 37
  • [8] Effectiveness of glucagon-like peptide-1 agonists in type 2 diabetes
    Pavlicek, Vojtech
    DIABETOLOGIE, 2023, 19 (03): : 359 - 360
  • [9] Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes
    Edwards, C. M. B.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (04) : 198 - 201
  • [10] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Ju-Ming Lu
    Advances in Therapy, 2019, 36 : 798 - 805